OostNL

AMT Medical B.V., established in 2015 and located in Ede, the Netherlands, specializes in the development of innovative medical devices for heart bypass surgery. The company's flagship product, the AMT Heart Bypass System, utilizes a minimal invasive technique known as the ELANA bypass, which was invented by neurosurgeon Prof. Dr. C.A.F. Tulleken and his research team. This advanced technology aims to enhance traditional heart bypass procedures by making them faster, safer, and less invasive, thereby improving patient outcomes and reducing complications. AMT Medical has completed the full development of its product and the production process, with all pre-clinical trials successfully concluded. The company is also preparing to initiate a clinical multi-center trial to further validate the technology's efficacy.

Tagworks Pharmaceuticals is a privately held biotech company based in the Netherlands, established in 2011 as a spin-out from Philips Healthcare. The company focuses on developing innovative in vivo chemistry to enhance the effectiveness of cancer therapies and to facilitate novel companion diagnostics. Operating from the Radboud University Medical Center in Nijmegen, Tagworks specializes in antibody-based imaging and therapy technologies. Its proprietary approach allows for the selective chemical manipulation of tagged antibodies in vivo, which improves the efficacy of established methods like radioimmuno-imaging and antibody-drug conjugates. This technology enables medical professionals to conduct imaging with significantly reduced radiation exposure for patients.

Delta Diagnostics, founded in 2018 as a spin-off from TNO – The Netherlands Organisation for Applied Scientific Research, specializes in the commercialization of advanced biosensor technology. The company focuses on developing photonic biosensors that integrate optical chips with waveguides to facilitate multiplexed biosensing. This technology enables real-time monitoring through highly sensitive refractive index sensors, allowing for label-free biosensing. Delta Diagnostics aims to provide rapid, sensitive, and cost-effective solutions that can significantly enhance research in the Life Sciences sector. By enabling accurate measurement of multiple biomarkers within minutes, the company aspires to drive new discoveries and foster the development of innovative diagnostics.

Prolira BV is a medical technology company based in Utrecht, the Netherlands, founded in 2015. It specializes in developing DeltaScan, an innovative EEG-based medical device designed for the early detection of delirium, a form of acute brain failure. The DeltaScan system comprises a single-use electrode patch known as the DeltaScan Patch and a hardware/software module called the DeltaScan Monitor, which analyzes brain activity to support clinical decision-making. Prolira is dedicated to enabling timely and effective treatment for acute encephalopathy and delirium, conditions that affect approximately 20 million patients annually in hospitals across the European Union and the United States. By providing the first EEG bedside device with a validated proprietary algorithm, Prolira aims to help clinicians optimize patient recovery, ultimately reducing long-term cognitive impairment and hospital costs.

ATRO Medical B.V., based in Nijmegen, the Netherlands, specializes in the development of anatomically shaped polymer meniscus implants, specifically the Trammpolin. This innovative prosthesis is designed to replace damaged menisci, restoring their protective function by acting as a joint spacer and shock absorber. The Trammpolin mimics the natural meniscus, facilitating adequate load distribution within the knee joint, which can provide significant relief for osteoarthritis patients suffering from severe pain. ATRO Medical emerged as a spin-out from DSM and Radboudumc, leveraging expertise from a public-private collaboration initiated in 2010 that involved various universities, private companies, and support from the Dutch government. This collaborative effort has been instrumental in the design and development of the Trammpolin prototype.

ScreenPoint Medical develops artificial intelligence software for breast imaging, including Transpara, to assist radiologists in reading digital breast tomosynthesis and mammography. The company focuses on deep learning and image analysis for automated interpretation of breast scans, leveraging large curated image databases and an understanding of mammography physics and clinical deployment. Its technology aims to improve early cancer detection, increase diagnostic consistency, and reduce unnecessary recalls, helping physicians screen for breast cancer earlier and enable less invasive treatment options.

InteRNA Technologies B.V. is a biotechnology company focused on developing microRNA (miRNA)-based therapeutics for cancer treatment. Founded in 2006 and headquartered in Nijmegen, the Netherlands, with a research and development center in Utrecht, the company leverages its proprietary technology to discover and validate miRNA sequences that can target multiple signaling pathways involved in cancer initiation, progression, and metastasis. By addressing previously undruggable targets, InteRNA aims to enhance the efficacy of existing cancer therapies and reduce the development of drug resistance. The company employs advanced bioinformatics and massively parallel sequencing techniques to analyze miRNA functions, paving the way for innovative treatment options in oncology.

Eurekite BV, based in Enschede, the Netherlands, specializes in the manufacture of flexible ceramic materials. Established in May 2015 as a spin-off from the University of Twente, the company focuses on the development and commercialization of its innovative technology, known as Flexiramics®. This technology emerged from the Inorganic Materials Science Group of the MESA + Institute for Nanotechnology, led by Professor Andre ten Elshof. Eurekite combines expertise in formulation chemistry, production technology, and composite development, with its disruptive materials attracting investment from prominent venture capital firms.

Pepscope is a Dutch biotechnology company that develops endogenous protein kinase activity profiling technologies, including QuantaKinome, a platform used by pharmaceutical companies and academic researchers to study kinase activity and support the discovery and development of kinase inhibitors and other therapies. The company focuses on profiling protein activity to reveal new applications for existing compounds and to guide therapy development. Its offerings span microarray- and mass spectrometry-based proteomics services and kinase profiling assays, enabling reproducible results and robust longitudinal studies. Founded in 2012 and based in Nijmegen, Pepscope aims to provide actionable proteomics insights to the pharmaceutical industry and researchers.

Prolira BV is a medical technology company based in Utrecht, the Netherlands, founded in 2015. It specializes in developing DeltaScan, an innovative EEG-based medical device designed for the early detection of delirium, a form of acute brain failure. The DeltaScan system comprises a single-use electrode patch known as the DeltaScan Patch and a hardware/software module called the DeltaScan Monitor, which analyzes brain activity to support clinical decision-making. Prolira is dedicated to enabling timely and effective treatment for acute encephalopathy and delirium, conditions that affect approximately 20 million patients annually in hospitals across the European Union and the United States. By providing the first EEG bedside device with a validated proprietary algorithm, Prolira aims to help clinicians optimize patient recovery, ultimately reducing long-term cognitive impairment and hospital costs.

Plasmacure develops a cold plasma technology to treat chronic wounds, with a focus on diabetic foot ulcers. Based in Eindhoven, the Netherlands, the company aims to stimulate healing by killing bacteria, promoting cell proliferation, and improving microcirculation, thereby reducing the risk of amputation and enhancing patient quality of life.

SuperBuddy is an on-demand grocery delivery service based in the Netherlands. The company operates an online marketplace that allows users to shop for groceries from local stores. By connecting customers with personal shoppers, SuperBuddy facilitates a tailored shopping experience where users can specify their preferences. The platform ensures timely delivery, typically within a two-hour window, enabling customers to conveniently receive their selected items at their doorstep.

Sound Energy BV is focused on developing and commercializing innovative technologies aimed at reducing fossil energy consumption. The company specializes in Thermo Acoustic Technology, which provides a sustainable solution for climate control in buildings. By utilizing hot water for cooling, Sound Energy's heat engines and heat pumps eliminate the need for electricity or gas, allowing homeowners to manage energy consumption while achieving zero carbon dioxide emissions. With a commitment to sustainability, the company integrates environmental considerations with scientific expertise and a pragmatic business approach, ensuring that its technologies serve both ecological and economic interests.